Literature DB >> 3319501

Treatment of respiratory tract infections with cephalosporin antibiotics.

R Finch1.   

Abstract

Infections of the respiratory tract are among the most common causes for antibiotic prescribing. Their diagnosis within the community is generally limited to clinical criteria, and microbiological information is frequently lacking. Hospitalised patients with respiratory tract infections are more likely to undergo diagnostic sampling, but difficulties remain in reliably defining a microbial aetiology, thereby providing a confident basis for antibiotic selection. In considering the role of the cephalosporins in the treatment of respiratory tract infections, over 500 published articles have been reviewed. The pharmacokinetic considerations are discussed and the limitations of existing methodology are emphasised. Individual agents are reviewed by site of sepsis and conclusions are drawn from both comparative and non-comparative studies and in relation to currently recommended regimens. Although oral cephalosporins are widely used to treat upper respiratory tract infections, none is considered ideal, especially where Haemophilus influenzae is pathogenic. In the case of lower respiratory tract infections the beta-lactamase stable parenteral cephalosporins have become widely used to treat pneumonia in hospitalised patients, especially where Gram-negative enteric bacilli are of aetiological importance. However, the lack of activity of these drugs against Legionella spp., Mycoplasma pneumoniae and Coxiella burnetii must be emphasised. Another area of increasing use is in the treatment of infective exacerbations in patients suffering from cystic fibrosis of the lungs where Pseudomonas aeruginosa is pathogenic; ceftazidime in particular has proved a useful alternative to earlier antipseudomonal penicillin antibiotics.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319501     DOI: 10.2165/00003495-198700342-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  150 in total

1.  A comparative trial of cephaloridine and erythromycin in hospitalized pneumonic patients.

Authors:  G Sterner; H Fransén; G Tunevall; A Svedmyr
Journal:  Postgrad Med J       Date:  1967-08       Impact factor: 2.401

2.  Ceftazidime in cystic fibrosis.

Authors:  B Gordts; I Dab; J P Butzler
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

3.  Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia.

Authors:  A Saito
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

4.  A multicentre prospective randomized trial comparing ceftazidime with cefazolin/tobramycin in the treatment of hospitalized patients with non-pneumococcal pneumonia.

Authors:  L A Mandell; L E Nicolle; A R Ronald; R Duperval; H G Robson; R Feld; J Vincelette; I Fong
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

Review 5.  Penetration of antibiotics into respiratory secretions.

Authors:  J E Pennington
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  The use of cefotaxime in the treatment of gram-positive pneumonias.

Authors:  S G Jenkinson
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia.

Authors:  B G Petty; C R Smith; J C Wade; G L Conrad; J J Lipsky; J J Ellner; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1978-07       Impact factor: 5.191

8.  Treatment of acute bacterial bronchitis and pneumonia with cefaclor.

Authors:  W J Mogabgab; B Pollock; R B Beville; L O Gentry; J G Jemsek
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

9.  Myringotomy in the treatment of acute otitis media in children.

Authors:  H Puhakka; E Virolainen; E Aantaa; P Tuohimaa; J Eskola; O Ruuskanen
Journal:  Acta Otolaryngol       Date:  1979       Impact factor: 1.494

10.  Ceftriaxone for the treatment of serious infections.

Authors:  R W Steele; R W Bradsher
Journal:  Am J Dis Child       Date:  1983-11
View more
  6 in total

1.  Cost-effectiveness opportunities for new antibiotics.

Authors:  A Hillman
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 2.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Pharmacokinetic properties of the cephalosporins.

Authors:  T Bergan
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 4.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

5.  Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia.

Authors:  C Carbon; P Léophonte; P Petitpretz; J P Chauvin; J Hazebroucq
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

6.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.